Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes
NCT ID: NCT00214136
Last Updated: 2021-08-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
30 participants
INTERVENTIONAL
2005-03-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
NCT02177292
Intensity Modulated Radiation Therapy for Prostate Cancer
NCT00214422
Phase I/II Hypofractionated Radiotherapy for Prostate Cancer
NCT00214097
Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
NCT00946543
Radiation Therapy in Treating Patients With Prostate Cancer
NCT01434290
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
prostate radiation to 70Gy, lymph nodes to 56Gy
radiotherapy
prostate radiation to 70Gy; nodal radiation to 56Gy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radiotherapy
prostate radiation to 70Gy; nodal radiation to 56Gy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Predicted risk of lymph node involvement \> 15%
* Gleason \> 7
Exclusion Criteria
* Use of anti-coagulant therapy
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Ritter, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Wisconsin Carbone Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2004-0472
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-00947
Identifier Type: REGISTRY
Identifier Source: secondary_id
A533300
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH\HUMAN ONCOLOGY
Identifier Type: OTHER
Identifier Source: secondary_id
RO04807
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.